Arca
Skip to content
Tools
Tools

Peptidoglycan

Macromolecule in Bacteria that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 3
  • In phases 1 to 3: 2
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2
  • Protein or peptide 1
  • Other 2

Approved3

  • Vancomycin
  • Dalbavancin
  • Oritavancin

Phase 31

  • Teicoplanin

Phase 21

  • Cefilavancin

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 5 act as: Peptidoglycan inhibitor; the rest name their own mechanism.
    VancomycinBoxed warningApprovedReseluteSmall moleculeInhibitor134
    DalbavancinApprovedAbbVieProtein or peptideInhibitor7
    OritavancinApprovedMelinta TherapeuticsSmall moleculeInhibitor2
    TeicoplaninPhase 3Novartis PharmaceuticalsOtherDisrupting agentPeptidoglycan disrupting agent9
    CefilavancinPhase 2Theravance BiopharmaOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
    Primary Sclerosing Cholangitis After Liver Transplant With Oral VancomycinVancomycinPhase 1Not yet recruitingYael R. NobelNov 18, 2026
    Ceftazidime Safety and Efficacy in the Prevention of Surgical Site InfectionsVancomycinPhase 2Enrolling by invitationUniversity of UtahNov 12, 2026
    Local Antibiotic Delivery From an Intramedullary Nail After Surgical Treatment of Tibial Fractures at High Risk of InfectionVancomycinNot applicableNot yet recruitingReselute, Inc.Nov 10, 2026
    Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)VancomycinPhase 1 / Phase 2RecruitingMetagen Therapeutics, Inc.Nov 3, 2026
    Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial FluidVancomycin—Not yet recruitingNutromicsOct 23, 2026
    Rutin and Ascorbic Acid for Prevention of Vancomycin-Induced Nephrotoxicity in Adult Patients" - a Clinical Trial Protocol Evaluating Whether Combined Rutin/Vitamin C Supplementation Reduces Kidney Toxicity From Vancomycin, Compared to Vitamin C Alone and Control.VancomycinNot applicableEnrolling by invitationAin Shams UniversityOct 14, 2026
    Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial InfectionsDalbavancin—Not yet recruitingKirby InstituteOct 5, 2026
    A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI ParticipantsVancomycinPhase 2RecruitingTenNor Therapeutics (Zhongshan) LimitedOct 5, 2026
    Exploring the Combination of Intracalvariosseous and Intravenous Antibiotics for Moderate to Severe Bacterial MeningitisVancomycinNot applicableNot yet recruitingyilong WangSep 17, 2026
    Dalbavancin Therapy for Infective EndocarditisDalbavancinPhase 3Not yet recruitingStefan HagelJul 13, 2026
    Early Discontinuation of Antibiotics in Paediatric High-risk Febrile NeutropeniaTeicoplaninPhase 4Not yet recruitingHospital Universitari Vall d'Hebron Research InstituteMay 15, 2026
    Oritavancin for Treatment of Serious Cardiac InfectionsOritavancinPhase 2Not yet recruitingKirby InstituteApr 24, 2026
    Oritavancin for CIED Infections With MDR Gram-positive CocciOritavancinNot applicableRecruitingMedical University of SilesiaJun 10, 2025
    Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review StudyTeicoplanin—Active, not recruitingNational Taiwan University HospitalMay 6, 2025
    Efficacy and Safety of Dalbavancin As Suppressive TherapyDalbavancin—RecruitingHospices Civils de LyonMar 28, 2025
    Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.TeicoplaninNot applicableRecruitingInstitute of Liver and Biliary Sciences, IndiaFeb 10, 2025
    A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk LeukemiaDalbavancinPhase 1RecruitingSt. Jude Children's Research HospitalFeb 5, 2025
    Teicoplanin Allergy Testing Using Autologous Serum (TATAS)TeicoplaninNot applicableRecruitingUniversity Hospital Southampton NHS Foundation TrustJan 31, 2025
    Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Malignancy or Critical IllnessTeicoplanin—Not yet recruitingNational Taiwan University HospitalNov 5, 2024
    Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)TeicoplaninNot applicableRecruitingUniversity Hospital, GhentMay 23, 2024
    Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.Dalbavancin, TeicoplaninPhase 4RecruitingFundación Pública Andaluza para la gestión de la Investigación en SevillaMay 21, 2024
    Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus AureusDalbavancinPhase 3RecruitingAssistance Publique - Hôpitaux de ParisNov 11, 2021
    Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee ReplacementsDalbavancinNot applicableActive, not recruitingCentre Hospitalier Universitaire de NiceSep 16, 2021
    PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4TeicoplaninNot applicableRecruitingMedical University of ViennaJan 11, 2016

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3041361, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.